Navigation Links
Proteolix Raises $79 Million in Series C Financing
Date:9/8/2008

d-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

Carfilzomib is currently in Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. In non- clinical studies, carfilzomib has consistently exhibited a high level of selectivity for a single active site in the proteasome, and the reported clinical data to-date indicate the drug is well tolerated. The company's most advanced clinical trials of carfilzomib are evaluating the compound's activity among multiple myeloma patients who have failed or relapsed following prior therapy. In addition to carfilzomib, Proteolix has generated a rich pipeline, including an oral anti-cancer proteasome inhibitor as well as a selective inhibitor targeting the proteasome in the cells of the immune system.

New Board Member Announced

Proteolix is also pleased to announce that Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals, Inc., has joined its Board of Directors. Mr. Hastings brings more than 20 years of biotechnology and pharmaceutical industry experience as a senior-level executive in public and private companies. "Proteolix has made great progress in advancing its lead cancer therapeutic through clinical trials and developing an earlier stage pipeline of proteasome inhibitors," said Mr. Hastings on behalf of Proteolix's Board of Directors. "I personally look forward to working closely with the team on their continued success."

Mr. Hastings also serves on the board of directors of Cerimon Pharmaceuticals, Inc. and serves as a director of the Biotechnology Industry Organization (BIO) and BayBIO.

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Pearl Therapeutics Raises $15.5 Million in Private Financing
4. Enobia Pharma Raises $40.1 Million Series B Financing
5. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
6. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
7. VisEn Medical Raises $7 Million in Series B Financing
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 Permian Plastics, http://www.permianplastics.com ... Louis, Missouri, area on October 24th, 1994. Since ... plastic injection molder in the Midwest. The company operates ... supplier to many Fortune 500 clients. , Permian Plastics ... of the way, from concept to completion, going the ...
(Date:10/2/2014)... 02, 2014 The National Institutes ... (LLNL) a grant today to develop an electrode ... understand how the brain works through unprecedented resolution ... of NIH's efforts to support President Obama's BRAIN ... new research effort to revolutionize our understanding of ...
(Date:10/2/2014)... 2 de octubre de 2014 Laborie Medical ... Ontario , ha completado la adquisición de Unisensor ... Unisensor tiene su sede central sita en Wiesendangen, Suiza, ... Portsmouth, New Hampshire . Unisensor está ... de alta resolución para evaluar la presión y valores ...
(Date:10/2/2014)... WALTHAM, Mass. , Oct. 2, 2014 /PRNewswire/ ... and Drug Administration has granted Fast Track designation ... for the treatment of sickle cell disease.  NKTT120 ... iNKT cells, a regulatory T cell that has ... organ damage in preclinical models of sickle cell ...
Breaking Biology Technology:Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... ANTONY, France, July 10 , - 1st Half-Year Sales Up 16%, - Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal,to)12%, EUR millions ... 07/06 2008 08/07 ... ... Europe (1) 20.5 72 23.2 72 13 26.8 71 ...
... July 10 Today,s Pharmaceutical Research,and ... to end the practice,of providing non-educational ... toward,enhancing the value of the physician/industry ... CMR Institute, a leading non-profit,organization dedicated ...
... July 10 Quest Diagnostics,Incorporated (NYSE: DGX ), ... announced today that its second-quarter,2008 results will be made ... that it will hold its quarterly conference call with ... on that day., The public may access the ...
Cached Biology Technology:Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2CMR Institute: Education Key to Physician/Representative Relationship 2Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... food safety and traceability will be showcased at a ... The Food Integrity and Traceability Conference will take place ... leading scientists, food standards regulators and agri-food producers from ... Institute for Global Food Security and from across the ...
... BRCA2 gene have a worse prognosis and lower survival rates ... This is the main conclusion to come out of a ... Oncology , in which David Olmos, Head of the Prostate ... National Cancer Research Centre (CNIO), has taken part in, along ...
... making the disease difficult to study. However, K9 bone ... the disease, and over 10,000 canine patients develop the ... Cancer Center and the Colorado State University Flint Animal ... used easily available K9 osteosarcoma samples to discover a ...
Cached Biology News:International conference will put agri-food supply chain under the microscope 2First genetic factor in prostate cancer prognosis identified 2AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer 2
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
... These 2800mL wide mouth PYREX Fernbach-style culture ... center of the flask bottom to achieve ... triple baffled flasks have a Delong-style 38mm ... steel closures. For plastic closures see Nos. ...
... template is designed to allow neomycin/kanamycin selection ... FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance gene ... expression of kanamycin resistance in E.coli ... expression of neomycin resistance in mammalian cells. ...
Biology Products: